Veradermics (MANE) Total Current Liabilities (2024 - 2026)
Veradermics' (MANE) quarterly Total Current Liabilities came in at $6.7 million in Q1 2026, down 26.62% on a QoQ basis from $9.2 million in Q4 2025.
Analysis
Veradermics (MANE) Total Current Liabilities (2024 - 2026) Analysis & Trends
Veradermics (MANE) has 3 years of Total Current Liabilities data on file, last reported at $6.7 million in Q1 2026.
- Quarterly Total Current Liabilities changed N/A year-over-year to $6.7 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $6.7 million (changed N/A YoY) and the FY2025 annual result came in at $9.2 million, up 93.98% from the prior year.
- Total Current Liabilities eased to $6.7 million in Q1 2026, from $9.2 million in the prior quarter.
- In the past five years, Total Current Liabilities ranged from a high of $9.2 million in Q4 2025 to a low of $4.7 million in Q4 2024.
- A 3-year average of $6.9 million and a median of $6.7 million in 2026 frame the typical range for Total Current Liabilities.
- The widest YoY moves for Total Current Liabilities: up 93.98% in 2025, down 93.98% in 2025.
- Tracing MANE's Total Current Liabilities over 3 years: stood at $4.7 million in 2024, then surged by 93.98% to $9.2 million in 2025, then declined by 26.62% to $6.7 million in 2026.
- The last three Total Current Liabilities figures came in at $6.7 million (Q1 2026), $9.2 million (Q4 2025), and $4.7 million (Q4 2024), per Business Quant data.
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Total Current Liabilities (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 138.47 Bn | 130.62 Bn | 2.84 Bn | 3.94 Bn |
| 2 | Regeneron Pharmaceuticals | 85.18 Bn | 77.19 Bn | 3.93 Bn | 5.53 Bn |
| 3 | Argenx Se | 63.38 Bn | 58.19 Bn | 1.37 Bn | 1.58 Bn |
| 4 | Moderna | 58.09 Bn | 52.95 Bn | 52.00 Mn | 2.53 Bn |
| 5 | Revolution Medicines | 44.33 Bn | 44.33 Bn | - | 354.06 Mn |
| 6 | BeOne Medicines | 40.02 Bn | 34.92 Bn | 1.53 Bn | 2.12 Bn |
| 7 | Alnylam Pharmaceuticals | 35.57 Bn | 32.27 Bn | 992.69 Mn | 1.51 Bn |
| 8 | Royalty Pharma | 28.45 Bn | 27.61 Bn | - | 630.93 Mn |
| 9 | Insmed | 27.48 Bn | 26.32 Bn | 358.27 Mn | 438.74 Mn |
| 10 | Veradermics | 3.96 Bn | 3.96 Bn | - | 11.69 Mn |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Jun 30, 2026 | 11.69 Mn |
| Mar 31, 2026 | 6.72 Mn |
| Dec 31, 2025 | 9.15 Mn |
| Dec 31, 2024 | 4.72 Mn |